Rodabe N Amaria Selected Research

Immune Checkpoint Inhibitors

7/2023	Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.
12/2021	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
10/2021	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.
1/2021	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
12/2020	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment.
1/2020	B cells and tertiary lymphoid structures promote immunotherapy response.
1/2019	Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials.
12/2018	Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
12/2018	Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
11/2018	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodabe N Amaria Research Topics

Disease

54	Melanoma (Melanoma, Malignant) 06/2023 - 09/2011
31	Neoplasms (Cancer) 07/2023 - 05/2014
5	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2018
4	Disease Progression 01/2018 - 03/2016
3	Brain Neoplasms (Brain Tumor) 01/2020 - 05/2014
2	Blister (Bulla) 07/2023 - 07/2018
2	Exanthema (Rash) 01/2022 - 01/2021
2	Breast Neoplasms (Breast Cancer) 01/2019 - 10/2008
2	Uveal melanoma 11/2018 - 01/2017
1	Bullous Pemphigoid (Pemphigoid) 07/2023
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Anemia 01/2022
1	Neoplasm Micrometastasis 01/2022
1	Diarrhea 01/2022
1	Edema (Dropsy) 01/2022
1	Fatigue 01/2022
1	Skin Neoplasms (Skin Cancer) 01/2022
1	Nausea 01/2022
1	Urinary Retention 09/2021
1	Ovarian Neoplasms (Ovarian Cancer) 01/2021
1	Adenocarcinoma of Lung 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	T-Cell Lymphoma (Lymphoma, T Cell) 12/2020
1	Tertiary Lymphoid Structures 01/2020
1	Pathologic Complete Response 01/2020
1	Anus Neoplasms (Anal Cancer) 01/2019
1	Squamous Cell Carcinoma of Head and Neck 01/2019
1	Headache (Headaches) 01/2018
1	Fever (Fevers) 01/2018
1	Chills 01/2018
1	Necrosis 12/2017
1	Hemorrhage 12/2017
1	Carcinogenesis 09/2011
1	Multiple Sclerosis 10/2008

Drug/Important Bio-Agent (IBA)

16	Immune Checkpoint InhibitorsIBA 07/2023 - 10/2014
12	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 05/2014
6	NivolumabIBA 03/2023 - 07/2018
4	IpilimumabIBA 01/2022 - 09/2011
3	Interleukin-2 (IL2)IBA 11/2018 - 01/2015
3	trametinibIBA 01/2018 - 05/2014
3	dabrafenibIBA 01/2018 - 05/2014
2	relatlimabIBA 03/2023 - 11/2022
2	AntigensIBA 01/2022 - 11/2014
2	binimetinibIBA 01/2022 - 01/2020
2	cyclopropapyrroloindoleIBA 01/2022 - 01/2022
2	Messenger RNA (mRNA)IBA 10/2021 - 01/2018
2	CytokinesIBA 01/2019 - 01/2015
1	Toll-Like Receptor 4IBA 07/2023
1	Complement System Proteins (Complement)IBA 07/2023
1	pembrolizumabIBA 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	ribociclibIBA 01/2022
1	Dietary Fiber FDA Link 12/2021
1	atezolizumabIBA 12/2021
1	Pantothenic Acid (Calcium Pantothenate)FDA Link 12/2021
1	Coenzyme A (CoA)IBA 12/2021
1	Keratins (Keratin)IBA 10/2021
1	MicroRNAs (MicroRNA)IBA 10/2021
1	Immune Checkpoint ProteinsIBA 10/2021
1	Oxygen (Dioxygen)IBA 09/2021
1	Aurora KinasesIBA 04/2021
1	Proteins (Proteins, Gene)FDA Link 04/2021
1	Sorafenib (BAY 43-9006)FDA Link 01/2021
1	VemurafenibIBA 01/2021
1	CrizotinibIBA 01/2021
1	AntibodiesIBA 01/2021
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	encorafenibIBA 01/2020
1	T-Lymphocyte Differentiation Antigens (Antigens, Differentiation, T Lymphocyte)IBA 01/2019
1	CathelicidinsIBA 07/2018
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2018
1	Interleukin-9 (Interleukin 9)IBA 01/2018
1	Investigational DrugsIBA 01/2018
1	3' Untranslated Regions (3' UTR)IBA 01/2018
1	HLA-A Antigens (HLA-A)IBA 01/2018
1	Bevacizumab (Avastin)FDA Link 12/2017
1	Temozolomide (Temodar)FDA LinkGeneric 12/2016
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2016
1	Fluorine-18IBA 02/2016
1	aldesleukin (Proleukin)FDA Link 01/2015
1	Proto-Oncogene Proteins B-rafIBA 05/2014
1	Mitogen-Activated Protein KinasesIBA 05/2014
1	HLA-DR Antigens (HLA-DR)IBA 11/2013
1	Monoclonal AntibodiesIBA 09/2011

Therapy/Procedure

38	Therapeutics 07/2023 - 09/2011
17	Immunotherapy 06/2023 - 01/2015
8	Neoadjuvant Therapy 01/2023 - 07/2018
2	Lymph Node Excision (Lymph Node Dissection) 01/2023 - 07/2021
2	Radiotherapy 09/2022 - 12/2017
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2018
2	Precision Medicine 01/2017 - 01/2016
1	Ostomy 09/2022
1	Chest Tubes (Chest Tube) 09/2021
1	Blood Transfusion (Blood Transfusions) 09/2021
1	Operative Time 01/2020
1	Injections 07/2018
1	Aftercare (After-Treatment) 07/2018
1	Withholding Treatment 01/2017